IMU 4.76% 2.2¢ imugene limited

News: Imugene progressing cancer vaccine towards clinical studies

  1. Imugene (ASX:IMU) is preparing to initiate this year the clinical program for its Her-Vaxx peptide vaccine, a B-cell based immunotherapy for HER-2 positive gastric & breast cancer.

    Her-Vaxx has potential to improve upon Roche’s blockbuster Herceptin drug that generated annualised sales of $6.9 billion and targets the same biomarker.

    It was developed by one of Europe’s leading cancer institutes with about $10 million already invested in the technology.

    Charles Walker, managing director. outlined these points and many others at the February 2015 Proactive Investors Melbourne / Sydney Luncheons.

    The full presentation can be ACCESSED HERE.


watchlist Created with Sketch. Add IMU (ASX) to my watchlist
(20min delay)
Mkt cap $75.59M
Open High Low Value Volume
2.1¢ 2.2¢ 2.1¢ $315.2K 14.40M

Buyers (Bids)

No. Vol. Price($)
1 1450258 2.2¢

Sellers (Offers)

Price($) Vol. No.
2.3¢ 3495421 10
Last update - 16.10pm 19/10/2018 (20 minute delay) ?
0.00 ( 4.76 %)
Open High   Low Volume
2.2¢ 2.2¢   2.2¢ 4359465
Last updated 14.48pm 19/10/2018 (live) ?
IMU (ASX) Chart
GET SUPPORT arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.